black pepper extract Piperine 98%

What is pipperine:

Piperine is the alkaloid responsible for the pungency of black pepper and long pepper, along with chavicine (an isomer of piperine).Piperine is often added to prepared food to enhance aroma and flavor.It can Promote drug absorption, and improve the effectiveness of the drug function. In clinical practice, it can induce calm (sedative effect) or to induce sleep (hypnotic effect), and used to make anticonvulsant, antidepressant, and muscle relaxation drug.
 Piperine has also been found to inhibit human CYP3A4 and P-glycoprotein, enzymes important for the metabolism and transport of xenobiotics and metabolites.In animal studies, piperine also inhibited other enzymes important in drug metabolism.By inhibiting drug metabolism, piperine may increase the bioavailability of various compounds. Notably, piperine may enhance bioavailability of curcumin by 2000% in humans.

Staherb piperine main function:

1.With the function of lipid-lowering, anti-inflammatory, choleretic, anti-tumor and anti-oxidation;

2.It is a natural food coloring, having strong coloring ability, good heat resistance and light resistance.

3. Detoxication, Choleretic effect.

4. Antibacterial, anti-inflammatory.

5. Reducing blood-lipid, anti-hypertension.

6. Having the ability of termination Of pregnancy.

7.With the function of improving blood circulation and treating amenorrhea;

8.With the function of treating women’s dysmenorrhea and amenorrhea.

Staherb piperine application:

1. Piperine used to treat flatulence, gout, laryngitis, and paralysis.
2. Piperine used to treat abdominal tumors and gastric ulcers.
3. Piperine improve the digestive system.
4. Piperine enhances the immune system.

References:

  1. 1.Braman, S.S. 2006. The global burden of asthma. Chest 130: 4–12.
  2. 2.Dworski, R. 2000. Oxidant stress in asthma. Thorax 55: 51–53.
  3. 3.Calhoun, W.J., H.E. Reed, D.R. Moest, and C.A. Stevens. 1992. Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. The American Review of Respiratory Research 145: 317–325.
  4. 4.Sedgwick, J.B., K.M. Geiger, and W.W. Busse. 1990. Superoxide generation by hypodense eosinophils from patients with asthma. American Review of Respiratory Disease 142: 120–125.
  5. 5.Vachier, I., M. Damon, C. Le Doucen, A.C. De Paulet, P. Chanez, F.B. Michel, and P. Godard. 1992. Increased oxygen species generation in blood monocytes of asthmatic patients. American Review of Respiratory Disease 146: 1161–1168.
  6. 6.Hulsmann, A.R., H.R. Raatgeep, J.C. Den Hollander, T.H.E.O. Stijnen, P.R. Saxena, K.F. Kerrebijn, and J.C. de Jongste. 1994. Oxidative epithelial damage produces hyperresponsiveness of human peripheral airways. American Journal of Respiratory and Critical Care Medicine 149: 519–525.
  7. 7.Franco, R., A.C. Santos, H.F. do Nascimento, C. Souza-Machado, E. Ponte, A. Souza-Machado, S. Loureiro, M.L. Barreto, L.C. Rodrigues, and A.A. Cruz. 2007. Cost-effectiveness analysis of a state funded programme for control of severe asthma. Bio Med Central Public Health 7: 82.
  8. 8.Kumar, D., V. Arya, R. Kaur, Z.A. Bhat, V.K. Gupta, and V. Kumar. 2012. A review of immunomodulators in the Indian traditional health care system. Journal of Microbiology, Immunology and Infection 45: 165–184.
  9. 9.Manson, M. M., P. B. Farmer, A. Gescher, and W. P. Steward. 2005. Innovative agents in cancer prevention. In Tumor Prevention and Genetics III. Springer, Berlin, Heidelberg 257–275.
  10. 10.World Health Organization. 2008. Traditional Medicine Fact Sheet No. 134.
  11. 11.Aggarwal, B. B., Y. J. Surh, and S. Shishodia. 2007.Curcumin: The indian solid gold. The molecular targets and therapeutic uses of curcumin in health and disease. Springer Science & Business Media 595
  12. 12.Sandur, S.K., H. Ichikawa, M.K. Pandey, A.B. Kunnumakkara, B. Sung, G. Sethi, and B.B. Aggarwal. 2007. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radical Biology and Medicine 43: 568–580.
  13. 13.Reyes-Gordillo, K., J. Segovia, M. Shibayama, P. Vergara, M.G. Moreno, and P. Muriel. 2007. Curcumin protects against acute liver damage in the rat by inhibiting NF-κB, proinflammatory cytokines production and oxidative stress. Biochimica et Biophysica Acta (BBA)-General Subjects 1770: 989–996.
  14. 14.Xia, Y., L. Jin, B. Zhang, H. Xue, Q. Li, and Y. Xu. 2007. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sciences 80: 2161–2169
  15. 15.Polasa, K., A.N. Naidu, I. Ravindranath, and K. Krishnaswamy. 2004. Inhibition of B (a) P induced strand breaks in presence of curcumin. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 557: 203–213.
  16. 16.Ammon, H.P., and M.A. Wahl. 1991. Pharmacology of Curcuma longa. Planta Medica 57: 1–7.
  17. 17.Lee, S.A., S.S. Hong, X.H. Han, J.S. Hwang, G.J. Oh, K.S. Lee, M.K. Lee, B.Y. Hwang, and J.S. Ro. 2005. Piperine from the fruits of piper longum with inhibitory effect on monoamine oxidase and antidepressant-like activity. Chemical and Pharmaceutical Bulletin 53: 832–835.
  18. 18.Pradeep, C.R., and G. Kuttan. 2002. Effect of piperine on the inhibition of lung metastasis induced B16F-10 melanoma cells in mice. Clinical & Experimental Metastasis 19: 703–708.
  19. 19.Panda, S., and A. Kar. 2003. Piperine lowers the serum concentrations of thyroid hormones, glucose and hepatic 5′ D activity in adult male mice. Hormone and Metabolic Research 35: 523–526.
  20. 20.Koul, I.B., and A. Kapil. 1993. Evaluation of the liver protective potential of piperine, an active principle of black and long peppers. Planta Medica 59: 413–417.
  21. 21.Atal, C.K., R.K. Dubey, and J. Singh. 1985. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. Journal of Pharmacology and Experimental Therapeutics 232: 258–262.
  22. 22.Reen, R.K., D.S. Jamwal, S.C. Taneja, J.L. Koul, R.K. Dubey, F.J. Wiebel, and J. Singh. 1993. Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine. Biochemical Pharmacology 46: 229–238.
  23. 23.Shoba, G., D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P.S.S.R. Srinivas. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 64: 353–356.
  24. 24.Subhashini, P., S. Chauhan, S. Kumari, J.P. Kumar, R. Chawla, D. Dash, M. Singh, and R. Singh. 2013. Intranasal curcumin and its evaluation in murine model of asthma. International Immunopharmacology 17: 733–743.
  25. 25.Chauhan, P.S., D. Dash, and R. Singh. 2014. Intranasal curcumin attenuates airway remodeling in murine model of chronic asthma. International Immunopharmacology 21: 63–75.
  26. 26.Kumari, A., D. Dash, and R. Singh. 2015. Lipopolysaccharide (LPS) exposure differently affects allergic asthma exacerbations and its amelioration by intranasal curcumin in mice. Cytokine 76: 334–342.
  27. 27.Karaman, M., F. Firinci, S. Cilaker, P. Uysal, K. Tugyan, O. Yilmaz, N. Uzuner, and O. Karaman. 2012. Anti-inflammatory effects of curcumin in a murine model of chronic asthma. Allergologia et Immunopathologia 40: 210–214.
  28. 28.Bishnoi, M., K. Chopra, L. Rongzhu, and S.K. Kulkarni. 2011. Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence. Neurotoxicity Research 20: 215–225.
  29. 29.Kim, S.H., and Y.C. Lee. 2009. Piperine inhibits eosinophil infiltration and airway hyperresponsiveness by suppressing T cell activity and Th2 cytokine production in the ovalbumin-induced asthma model. Journal of Pharmacy and Pharmacology 61: 353–359.
  30. 30.Ram, A., M. Das, and B. Ghosh. 2003. Curcumin attenuates allergen-induced airway hyperresponsiveness in sensitized guinea pigs. Biological and Pharmaceutical Bulletin 26: 1021–1024.
  31. 31.Sahiner, U.M., E. Birben, S. Erzurum, C. Sackesen, and O. Kalayci. 2011. Oxidative stress in asthma. World Allergy Organization Journal 4: 151–158.
  32. 32.Kirkham, P., and I. Rahman. 2006. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacology & Therapeutics 111: 476–494.
  33. 33.Parra, A., M.L. Sanz, L. Vila, I. Prieto, I. Dieguez, and A.K. Oehling. 1999. Eosinophil soluble protein levels, eosinophil peroxidase and eosinophil cationic protein in asthmatic patients. Journal of Investigational Allergology & Clinical Immunology 9: 27.
  34. 34.Platts-Mills, T.A. 2001. The role of immunoglobulin E in allergy and asthma. American Journal of Respiratory and Critical Care Medicine 164: 1–5
  35. 35.Cho, Y.S., and H.B. Moon. 2010. The role of oxidative stress in the pathogenesis of asthma. Allergy, Asthma & Immunology Research 2: 183–187
  36. 36.Wood, L.G., P.G. Gibson, and M.L. Garg. 2003. Biomarkers of lipid peroxidation, airway inflammation and asthma. European Respiratory Journal 21: 177–186.

发表评论

电子邮件地址不会被公开。 必填项已用*标注